Prolor Biotech
Click here to view PROLOR's latest investor presentation December 2011
Updated presentation from the OPPENHEIMER ANNUAL HEALTHCARE CONFERENCE, DECEMBER 2011

Long-acting hGH scheduled for Phase III in 2012

Human growth hormone ($3 billion market, scheduled for Phase III in 2012) that could potentially be injected once a week or twice per month instead of daily injections. GLP-1 / Glucagon dual receptor agonist for Diabetes Type II that could be injected once a week ($2 billion market) that may have dramatically better weight-loss profile than current GLP-1 therapies. Long acting Factor VIIa and Factor IX for hemophilia ($2 billion market). Superior biobetter therapies for patients.

CTP -- Nature's Solution To Proteins' Longevity

CTP is a small peptide naturally found in the body as a portion of the hormone hCG, and in fact provides hCG with its superior longevity. We attach CTP to other proteins and significantly increase their lonevity as well.

Merck's FSH-CTP Approved In Europe Jan 2010

Merck and PROLOR have the exclusive license from Washington University to utilize the CTP technology. On January 28, 2010 the European Commission (EC) gave Merck & Co. marketing approval with unified labeling valid in all European Union Member States for FSH-CTP, now branded as ELONVA®.
Latest News
5/8/2012 PROLOR BIOTECH ANNOUNCES POSITIVE TOP-LINE RESULTS FROM FOUR-MONTH TREATMENT EXTENSION OF ITS LONG-ACTING HUMAN GROWTH HORMONE PHASE II TRIAL
Study of hGH-CTP Given Once Weekly to Growth Hormone Deficient Adults for Four Months Confirms Potential of Single Weekly Injection Protocol. Data Was Presented Today at the Joint 15th International Congress of Endocrinology and 14th European Congress of Endocrinology in Florence, Italy.
4/17/2012 PROLOR BIOTECH ANNOUNCES POSITIVE RESULTS OF ITS OBESITY/DIABETES DRUG CANDIDATE IN PRECLINICAL WEIGHT LOSS STUDY
MOD-6030 Administered Once-Weekly Over 30 Days Produced 28% Weight Loss and Improved Glycemic Profile. Other Potential Health Benefits Included 57% Reduction in Cholesterol Levels. Data to Be Presented at 5th Diabetes Drug Discovery and Development Conference.
2/14/2012 PROLOR BIOTECH ANNOUNCES POSITIVE PRECLINICAL RESULTS FROM COMPARATIVE STUDY OF ITS LONG-ACTING CLOTTING FACTOR VIIa
Factor VIIa-CTP May Provide Hemophilia Patients Prolonged Protection from Bleeding Episodes
1/18/2012 PROLOR BIOTECH ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PILOT STUDY OF ITS LONG-ACTING HUMAN GROWTH HORMONE INJECTED TWICE PER MONTH
Post-Phase II hGH-CTP Study Shows Promise for Regimen in Which 2 hGH-CTP Injections Per Month Could Replace Current Regimen of 30 Growth Hormone Injections Per Month.
8/4/2011 PROLOR BIOTECH ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE II TRIAL OF ITS LONG-ACTING HUMAN GROWTH HORMONE THAT ACHIEVED ALL KEY STUDY GOALS
Trial of hGH-CTP in Growth Hormone Deficient Adults Achieved Key Efficacy and Safety Endpoints. Positive Results Set Stage for Initiating Phase III Trial Expected to Begin in 2012.
7/8/2010 Globes: "I'd Like To See Teva In India and China" -- interview with Dr. Phillip Frost, Chairman of Teva and PROLOR Biotech
"I think Prolor is a great little company, and its small size is one of its main virtues. It is run and managed carefully by hard-working people who get things done efficiently. They currently have half-a-dozen drugs under development, each of which has the potential for over $1 billion in sales."
6/3/2010 PROLOR's Management Rings Opening Bell at NYSE
Chairman & CEO of NYSE, Duncan L. Niederauer, hosted a breakfast and bell-ringing ceremony to celebrate PROLOR's recent listing with NYSE
2/2/2010 PROLOR BIOTECH REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE I STUDY OF ITS LONGER-ACTING VERSION OF HUMAN GROWTH HORMONE
Data Show PROLOR’s Biobetter Form of hGH has Potential to Reduce Required Dosing Frequency from One Injection Per Day to Two Injections Per Month. Phase I Safety and Tolerability Endpoints Met.
1/29/2010 PROLOR BIOTECH REPORTS MERCK RECEIVES FINAL MARKETING AUTHORIZATION IN EUROPE FOR LONG-ACTING CTP-MODIFIED FERTILITY TREATMENT ELONVA® (FSH-CTP)
Merck and PROLOR are Both Licensees of the CTP Technology Used to Prolong the Duration of Merck’s Novel Fertility Drug ELONVA®. Supports the Clinical Efficacy and Safety of CTP Technology.
1/25/2010 REPORTS POSITIVE RESULTS FROM COMPARATIVE STUDY OF ITS LONGER-ACTING VERSION OF MULTIPLE SCLEROSIS DRUG INTERFERON BETA IN PRIMATES
Primate Study Shows Durability of PROLOR’s IFN-Beta-CTP Is Prolonged 13 Times and Drug Exposure is Prolonged 55 Times Compared to Commercially Available IFN-Beta. By Decreasing Frequency of Required Injections, IFN-Beta-CTP Could Provide Important Benefits to Multiple Sclerosis Patients
בניית אתרים
Copyright 2006 © PROLOR Biotech Inc.